Post‐Lipitor Treatment of Acute Coronary Syndrome: Focus on the Novel, Biologic Anti‐ PCSK9 AgentsLarry Gorkin, president of Gorkin & Cheddar Consulting, providesthought-provoking rhetoric through his myriad of written reports. Larry has agreed to present new and ...
Ivonescimab+AK117 近日,康方生物(9926.HK)宣布其自主研发的全球首创的PD-1/VEGF双特异性抗体依沃西联合新一代D47单抗莱法利(AK117)对比帕博利珠单抗一线治疗PD-L1阳性(CPS≥1)复发转移性头颈部鳞癌(R/M HNSCC)随机、对照、多中心、III期临床研究(AK117-302)完成首例患者入组。华中科技大学同济医学院附属协和医院...
9. The antibody of claim 1, wherein the heavy chain variable region comprises an amino acid sequence derived from residues 19-135 of SEQ ID NO:6, and wherein the light chain variable region comprises an amino acid sequence derived from residues 23-130 of SEQ ID NO:8. 10. The antibody...
[15,16]. More selective antibodies that bind to a range of pro-inflammatory cell types could give a more precise indication of plaque vulnerability. Co-stimulatory molecules are present in a plethora of cells, including immune cells, and have been demonstrated to play a key role in the ...
Lupin peptide T9 (GQEQSHQDEGVIVR) modulates the mutant PCSK9D374Y Pathway: In vitro characterization of its dual hypocholesterolemic behavior. Nutrients 2019, 11, 1665. [Google Scholar] [CrossRef] Muñoz, E.B.; Luna-Vital, D.A.; Fornasini, M.; Baldeón, M.E.; de Mejia, E.G. ...